Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ERAS | US
-0.18
-1.14%
Healthcare
Biotechnology
30/06/2024
10/03/2026
15.58
15.81
16.41
15.25
Erasca Inc. a clinical-stage biopharmaceutical company focuses on discovering developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007 an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer colorectal cancer and acute myeloid leukemia; and ERAS-601 an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801 a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego California.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
Weakness based on declining price with high volume
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
51.6%1 month
51.4%3 months
117.0%6 months
100.2%-
-
1.75
0.12
0.10
-1.57
-
-
-143.95M
4.24B
4.24B
-
-
-
-
-38.90
12.22
13.56
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
3.56
Range1M
5.00
Range3M
13.26
Rel. volume
1.31
Price X volume
78.06M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc | XENE | Biotechnology | 60.61 | 4.59B | -3.43% | n/a | 1.19% |
| Alkermes plc | ALKS | Biotechnology | 27.74 | 4.57B | -2.50% | 12.40 | 28.66% |
| TG Therapeutics Inc | TGTX | Biotechnology | 29.27 | 4.53B | 0.27% | 34.28 | 63.38% |
| CRISPR Therapeutics AG | CRSP | Biotechnology | 52.8 | 4.50B | -10.17% | n/a | 11.68% |
| Mirum Pharmaceuticals Inc | MIRM | Biotechnology | 90.93 | 4.34B | 2.42% | n/a | 138.24% |
| Amicus Therapeutics Inc | FOLD | Biotechnology | 14.36 | 4.26B | -0.07% | n/a | 335.08% |
| Scholar Rock Holding Corporation | SRRK | Biotechnology | 44.78 | 4.04B | 1.24% | n/a | 50.92% |
| Fluent Inc | COGT | Biotechnology | 36.68 | 4.01B | -0.89% | n/a | 4.87% |
| Ligand Pharmaceuticals Incorporated | LGND | Biotechnology | 212.29 | 3.88B | 1.98% | 45.66 | 0.98% |
| Viking Therapeutics Inc | VKTX | Biotechnology | 34.66 | 3.84B | 3.12% | n/a | 0.12% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Thor Industries Inc | THO | Recreational Vehicles | 84.71 | 4.48B | -1.37% | 23.44 | 27.88% |
| VeriFone Systems Inc | PAY | Building Products & Equipment | 26.02 | 3.24B | 0.93% | 102.46 | 2.10% |
| LCI Industries | LCII | Recreational Vehicles | 126.52 | 3.22B | -1.75% | 25.82 | 77.66% |
| Polaris Industries Inc | PII | Recreational Vehicles | 52.75 | 2.94B | 0.04% | 14.48 | 170.51% |
| Harley-Davidson Inc | HOG | Recreational Vehicles | 18.91 | 2.49B | 0.75% | 7.33 | 218.58% |
| HNI Corporation | HNI | Building Products & Equipment | 40.43 | 1.91B | -2.27% | 22.12 | 76.47% |
| Pitney Bowes Inc | PBI | Building Products & Equipment | 10.59 | 1.90B | -0.75% | n/a | -571.93% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 13.8 | 1.38B | -1.92% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 36.32 | 1.14B | 0.28% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 34.15 | 988.81M | -3.12% | 22.53 | 56.33% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.57 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.75 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 117.01 | 72.80 | Riskier |
| Debt to Equity | 0.12 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 4.24B | 3.66B | Par |